Journal of Clinical Oncology
Articles in this Issue
Head and neck cancers in Southeast Asia: 2022 incidence and mortality estimates for 2022 and projections for 2050.
e23281 Background: Head and neck cancers pose challenges due to their aggressive nature and complex treatment needs. In Southeast Asia (SEA), with over 69...
Survival of patients with anal small cell carcinoma: A perspective from the United States National Cancer Database.
e15505 Background: Anal canal malignancies, though relatively rare, are associated with significant clinical challenges. While the majority of anal cancer...
A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas.
8109 Background: With the limited efficacy of chemotherapy (carboplatin/paclitaxel) for advanced thymic carcinomas (TCs), better treatments are in need. I...
Mitoxantrone hydrochloride liposome combined with cytarabine (MA) for patients with newly diagnosed secondary acute myeloid leukemia.
6533 Background: Secondary acute myeloid leukemia (sAML) is an aggressive subset typically characterized by unfavorable biological features. CPX-351, a du...
A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data.
3115 Background: CDK2 inhibition could represent a novel treatment (tx) option for patients (pts) with resistance to CDK4/6 inhibitors (CDK4/6i) and/or in...
Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence.
e16276 Background: There is currently no internationally standardized adjuvant therapy for HCC patients with high-risk recurrence and metastasis after sur...
Aiding data retrieval in clinical trials with large language models: The APOLLO 11 Consortium in advanced lung cancer patients.
e23161 Background: Data retrieval is challenging in clinical research and traditional methods for data collection are often time-consuming and may be erro...
PEAR-GLIO: Clinical evaluation of an AI-driven functional precision medicine platform for therapeutic efficacy in gliomas.
TPS2093 Background: Gliomas and other primary brain tumors remain a leading cause of cancer-related mortality, with limited predictive biomarkers to guide...
The tumoral molecular landscape of long-term survivors with isocitrate dehydrogenase wildtype glioblastoma: Lessons from ETERNITY (EORTC 1419).
2059 Background: Predictors of long-term survival in patients with isocitrate dehydrogenase (IDH)-wildtype glioblastoma remain incompletely understood. ET...
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study.
1041 Background: The three antibody-drug conjugates (ADCs) — sacituzumab govitecan (SG), trastuzumab deruxtecan (T-DXd), and trastuzumab emtansine (T-DM1)...
Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors.
2644 Background: Although immune checkpoint inhibitors (ICIs) have heralded a new era in cancer treatment, many patients do not respond, underscoring the...
Molecular profiling and survival in oncogene-addicted resected stage IIIAN2 non-small cell lung cancer (NSCLC): A study from the Lung ART IFCT 0503 trial.
8026 Background: Molecular profiling is standard-of-care in metastatic NSCLC and increasingly important in earlier stages as personalized approaches arise...
Artificial intelligence in target discovery: CURE AI prediction of TIGIT and PD-L1 as immunotherapy targets in NSCLC.
e13692 Background: We developed CURE AI (Clinical trials Uncovering Real Efficacy Artificial Intelligence), a new type of machine learning platform that m...
Clinical utility of comprehensive transcriptome testing in advanced solid tumors.
3072 Background: Despite breakthroughs in genomically-matched therapies, many patients lack actionable genomic alterations. Consequently, innovative new s...
HIF1A⁺ macrophages as key mediators of immune suppression and recurrence in early-stage small cell lung cancer.
e20111 Background: Being the most aggressive pulmonary malignancy, early recurrence remains extremely common even in early-stage small cell lung cancer (S...
Opioid knowledge and concerns: Challenges among physicians in Turkey.
e13541 Background: The global opioid crisis highlights misuse risks, while Türkiye struggles with prescribing opioids due to knowledge gaps, biases, and i...
Efficacy of nivolumab in advanced esophageal carcinoma: A systematic review of phase III clinical trials.
e16051 Background: Nivolumab (NIVO) is an IgG4 anti-PD-1 monoclonal antibody, approved against advanced esophageal carcinoma (EC). Our study aimed to anal...
National Comprehensive Cancer Network guideline compliance in an oncology value-based care program serving Medicare members.
e23219 Background: Value-based care (VBC) focuses on improving patient health outcomes while reducing the overall cost of healthcare. The National Compreh...
EVEREST-1: Safety and efficacy data of A2B530, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with solid tumors associated with carcinoembryonic antigen (CEA) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
e16408 Background: A2B530 is a logic-gated CEA-targeting Tmod CAR T therapy being evaluated in the EVEREST-1 (NCT05736731) phase 1/2 study. Tmod CAR T the...
Real world treatment practices and outcomes of metastatic Merkel cell carcinoma: A retrospective study.
e21546 Background: Merkel cell carcinoma is an aggressive neuroendocrine skin cancer with frequent metastasis and a high mortality rate. Immunotherapy has...
Advancing global equity in cancer care: Comparative environmental impacts of radiotherapy in Brazil and the U.S.
1627 Background: Climate change poses a significant threat to global health, necessitating efforts to address the environmental impacts of oncology care,...
Racial disparities on incidence and survival in Kaposi sarcoma during the post-retroviral era: A Surveillance, Epidemiology and End Results program database (2000-2021) retrospective analysis.
e23570 Background: Kaposi Sarcoma is most observed in patients with human immunodeficiency virus (HIV). With the advent of the HAART, the incidence and pr...
Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers.
5037 Background: Bilateral TGCT provides a unique opportunity to elucidate a stem cell versus genetic origin of cancer. Comparison of the epigenetics and...
Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.
1019 Background: TROP2 (trophoblast cell surface antigen 2) is highly expressed in TNBC and associated with poor survival....
Racial disparities in hospitalization outcomes among adult patients with prostate cancer using the National Inpatient Sample (2018-2020).
e17007 Background: Racial disparities in prostate cancer management represent a significant health challenge with African American patients disproportiona...